Form 8-K - Current report:
SEC Accession No. 0001213900-25-010748
Filing Date
2025-02-06
Accepted
2025-02-06 09:22:18
Documents
16
Period of Report
2025-02-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0230157-8k_citius.htm   iXBRL 8-K 23908
2 PRESS RELEASE, DATED FEBRUARY 6, 2025 ea023015701ex99-1_citius.htm EX-99.1 36867
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4882
4 GRAPHIC ex99-1_002.jpg GRAPHIC 4920
  Complete submission text file 0001213900-25-010748.txt   259922

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctor-20250206.xsd EX-101.SCH 3018
6 XBRL LABEL FILE ctor-20250206_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE ctor-20250206_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0230157-8k_citius_htm.xml XML 3766
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-41534 | Film No.: 25595694
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)